Actualités Mylan NV - MYL | Actions NASDAQ

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101...

Proxy Statement (definitive) (def 14a)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION...

Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept

Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept PR...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filed by Mylan N.V. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...

Current Report Filing (8-k)

England 0001623613 false 0001623613 2020-05-29 2020-05-29 UNITED STATES SECURITIES AND...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...

Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®

- First neurotoxin formulation to be developed as a potential biosimilar product to BOTOX®, potentially giving Mylan access to 14 indications...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...

Current Report Filing (8-k)

false 0001623613 0001623613 2020-05-29 2020-05-29 UNITED STATES SECURITIES AND EXCHANGE...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...

Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings

Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings Mylan prepared to bring its...

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filed by Mylan N.V. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6(b) un...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Mylan NV (MYL)

Votre Hub pour des idées et discussions en direct en temps réel

MYL Actualités

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Current Report Filing (8-k)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Current Report Filing (8-k)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Mylan NV (MYL) Actualités

Mylan NV (MYL)

Votre Hub pour des idées et discussions en direct en temps réel

MYL Actualités

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Current Report Filing (8-k)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Current Report Filing (8-k)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités